Dalgard O - Search Results

1

Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.

Meijerink H, White RA, Løvlie A, de Blasio BF, Dalgard O, Amundsen EJ, Melum E, Kløvstad H. Meijerink H, et al. Among authors: dalgard o. BMC Infect Dis. 2017 Aug 3;17(1):541. doi: 10.1186/s12879-017-2631-2. BMC Infect Dis. 2017. PMID: 28774261 Free PMC article.

2

Follow-up studies of treatment for hepatitis C virus infection among injection drug users.

Dalgard O. Dalgard O. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S336-8. doi: 10.1086/427449. Clin Infect Dis. 2005. PMID: 15768344

3

[Hepatitis C--a health problem also in Norway].

Vik IS, Skaug K, Dalgard O, Steen TW, Hoddevik G. Vik IS, et al. Among authors: dalgard o. Tidsskr Nor Laegeforen. 2008 Feb 28;128(5):563-6. Tidsskr Nor Laegeforen. 2008. PMID: 18311199 Free article. Review. Norwegian.

4

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Moghaddam A, et al. Among authors: dalgard o. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154. Hepatology. 2011. PMID: 21374656 Clinical Trial.

5

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.

Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Eskesen AN, et al. Among authors: dalgard o. Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6. doi: 10.1097/MEG.0b013e3283546efd. Eur J Gastroenterol Hepatol. 2012. PMID: 22584257

6

All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study.

Kielland KB, Skaug K, Amundsen EJ, Dalgard O. Kielland KB, et al. Among authors: dalgard o. J Hepatol. 2013 Jan;58(1):31-7. doi: 10.1016/j.jhep.2012.08.024. Epub 2012 Sep 4. J Hepatol. 2013. PMID: 22960427

7

Hepatitis C virus reinfection following treatment among people who use drugs.

Grady BP, Schinkel J, Thomas XV, Dalgard O. Grady BP, et al. Among authors: dalgard o. Clin Infect Dis. 2013 Aug;57 Suppl 2:S105-10. doi: 10.1093/cid/cit301. Clin Infect Dis. 2013. PMID: 23884057 Review.

8

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Robaeys G, et al. Among authors: dalgard o. Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302. Clin Infect Dis. 2013. PMID: 23884061

9

Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.

Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. Kielland KB, et al. Among authors: dalgard o. J Hepatol. 2014 Feb;60(2):260-6. doi: 10.1016/j.jhep.2013.09.022. Epub 2013 Oct 2. J Hepatol. 2014. PMID: 24096048

10

HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984.

Kielland KB, Amundsen EJ, Dalgard O. Kielland KB, et al. Among authors: dalgard o. Scand J Gastroenterol. 2014 Dec;49(12):1465-72. doi: 10.3109/00365521.2014.968860. Epub 2014 Oct 13. Scand J Gastroenterol. 2014. PMID: 25310139

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206 results

Search Page

Filters